Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 52

1.

Results of a phase II clinical trial of 6-mercaptopurine (6MP) and methotrexate in patients with BRCA-defective tumours.

Roberts C, Strauss VY, Kopijasz S, Gourley C, Hall M, Montes A, Abraham J, Clamp A, Kennedy R, Banerjee S, Folkes LK, Stratford M, Nicum S.

Br J Cancer. 2019 Dec 9. doi: 10.1038/s41416-019-0674-4. [Epub ahead of print]

PMID:
31813938
2.

Probing the limits of Q-tag bioconjugation of antibodies.

Marculescu C, Lakshminarayanan A, Gault J, Knight JC, Folkes LK, Spink T, Robinson CV, Vallis K, Davis BG, Cornelissen B.

Chem Commun (Camb). 2019 Sep 19;55(76):11342-11345. doi: 10.1039/c9cc02303h.

3.

An essential role for dNTP homeostasis following CDK-induced replication stress.

Pai CC, Hsu KF, Durley SC, Keszthelyi A, Kearsey SE, Rallis C, Folkes LK, Deegan R, Wilkins SE, Pfister SX, De León N, Schofield CJ, Bähler J, Carr AM, Humphrey TC.

J Cell Sci. 2019 Mar 25;132(6). pii: jcs226969. doi: 10.1242/jcs.226969.

4.

Focused Ultrasound Hyperthermia for Targeted Drug Release from Thermosensitive Liposomes: Results from a Phase I Trial.

Gray MD, Lyon PC, Mannaris C, Folkes LK, Stratford M, Campo L, Chung DYF, Scott S, Anderson M, Goldin R, Carlisle R, Wu F, Middleton MR, Gleeson FV, Coussios CC.

Radiology. 2019 Apr;291(1):232-238. doi: 10.1148/radiol.2018181445. Epub 2019 Jan 15.

5.

A phase 1 study to assess the safety, tolerability, and pharmacokinetics of CXD101 in patients with advanced cancer.

Eyre TA, Collins GP, Gupta A, Coupe N, Sheikh S, Whittaker J, Wang LM, Campo L, Soilleux E, Tysoe F, Cousins R, La Thangue N, Folkes LK, Stratford MRL, Kerr D, Middleton MR.

Cancer. 2019 Jan 1;125(1):99-108. doi: 10.1002/cncr.31791. Epub 2018 Oct 17.

6.

Safety and feasibility of ultrasound-triggered targeted drug delivery of doxorubicin from thermosensitive liposomes in liver tumours (TARDOX): a single-centre, open-label, phase 1 trial.

Lyon PC, Gray MD, Mannaris C, Folkes LK, Stratford M, Campo L, Chung DYF, Scott S, Anderson M, Goldin R, Carlisle R, Wu F, Middleton MR, Gleeson FV, Coussios CC.

Lancet Oncol. 2018 Aug;19(8):1027-1039. doi: 10.1016/S1470-2045(18)30332-2. Epub 2018 Jul 11.

7.

A first-in-human phase I study to determine the maximum tolerated dose of the oral Src/ABL inhibitor AZD0424.

Woodcock VK, Clive S, Wilson RH, Coyle VM, Stratford MRL, Folkes LK, Eastell R, Barton C, Jones P, Kazmi-Stokes S, Turner H, Halford S, Harris AL, Middleton MR.

Br J Cancer. 2018 Mar 20;118(6):770-776. doi: 10.1038/bjc.2017.484. Epub 2018 Feb 13.

8.

CYP450 Enzymes Effect Oxygen-Dependent Reduction of Azide-Based Fluorogenic Dyes.

O'Connor LJ, Mistry IN, Collins SL, Folkes LK, Brown G, Conway SJ, Hammond EM.

ACS Cent Sci. 2017 Jan 25;3(1):20-30. doi: 10.1021/acscentsci.6b00276. Epub 2016 Dec 19.

9.

The anti-malarial atovaquone increases radiosensitivity by alleviating tumour hypoxia.

Ashton TM, Fokas E, Kunz-Schughart LA, Folkes LK, Anbalagan S, Huether M, Kelly CJ, Pirovano G, Buffa FM, Hammond EM, Stratford M, Muschel RJ, Higgins GS, McKenna WG.

Nat Commun. 2016 Jul 25;7:12308. doi: 10.1038/ncomms12308.

10.

Identification of vitamin B1 metabolism as a tumor-specific radiosensitizing pathway using a high-throughput colony formation screen.

Tiwana GS, Prevo R, Buffa FM, Yu S, Ebner DV, Howarth A, Folkes LK, Budwal B, Chu KY, Durrant L, Muschel RJ, McKenna WG, Higgins GS.

Oncotarget. 2015 Mar 20;6(8):5978-89.

11.

Biological consequences of radiation-induced DNA damage: relevance to radiotherapy.

Lomax ME, Folkes LK, O'Neill P.

Clin Oncol (R Coll Radiol). 2013 Oct;25(10):578-85. doi: 10.1016/j.clon.2013.06.007. Epub 2013 Jul 10. Review.

12.

DNA damage induced by nitric oxide during ionizing radiation is enhanced at replication.

Folkes LK, O'Neill P.

Nitric Oxide. 2013 Nov 1;34:47-55. doi: 10.1016/j.niox.2013.04.005. Epub 2013 Apr 26.

13.

Modification of DNA damage mechanisms by nitric oxide during ionizing radiation.

Folkes LK, O'Neill P.

Free Radic Biol Med. 2013 May;58:14-25. doi: 10.1016/j.freeradbiomed.2013.01.014. Epub 2013 Jan 29.

PMID:
23376236
14.

Kinetics of oxidation of tyrosine by a model alkoxyl radical.

Folkes LK, Bartesaghi S, Trujillo M, Radi R, Wardman P.

Free Radic Res. 2012 Sep;46(9):1150-6. doi: 10.3109/10715762.2012.695868. Epub 2012 Jun 20.

PMID:
22640268
15.

Quantitative determination of the anticancer prodrug combretastatin A1 phosphate (OXi4503, CA1P), the active CA1 and its glucuronide metabolites in human urine and of CA1 in plasma by HPLC with mass spectrometric detection.

Stratford MR, Folkes LK.

J Chromatogr B Analyt Technol Biomed Life Sci. 2012 Jun 1;898:1-6. doi: 10.1016/j.jchromb.2012.03.040. Epub 2012 Apr 24.

PMID:
22578514
16.

A validated HPLC method with fluorescence detection for the glucuronides of Combretastatin A1 in human plasma, and studies on their cis-trans isomerisation.

Stratford MR, Folkes LK.

J Pharm Biomed Anal. 2012 Mar 25;62:114-8. doi: 10.1016/j.jpba.2011.12.022. Epub 2011 Dec 24.

PMID:
22251460
17.

Phase I clinical and pharmacokinetic evaluation of the vascular-disrupting agent OXi4503 in patients with advanced solid tumors.

Patterson DM, Zweifel M, Middleton MR, Price PM, Folkes LK, Stratford MR, Ross P, Halford S, Peters J, Balkissoon J, Chaplin DJ, Padhani AR, Rustin GJ.

Clin Cancer Res. 2012 Mar 1;18(5):1415-25. doi: 10.1158/1078-0432.CCR-11-2414. Epub 2012 Jan 10.

18.

Validation of a method for the determination of the anticancer agent Combretastatin A1 phosphate (CA1P, OXi4503) in human plasma by HPLC with post-column photolysis and fluorescence detection.

Stratford MR, Folkes LK.

J Chromatogr B Analyt Technol Biomed Life Sci. 2011 Sep 1;879(25):2673-6. doi: 10.1016/j.jchromb.2011.07.014. Epub 2011 Jul 18.

PMID:
21820978
19.

Kinetics of reduction of tyrosine phenoxyl radicals by glutathione.

Folkes LK, Trujillo M, Bartesaghi S, Radi R, Wardman P.

Arch Biochem Biophys. 2011 Feb 15;506(2):242-9. doi: 10.1016/j.abb.2010.12.006. Epub 2010 Dec 11.

PMID:
21147061
20.

Break-induced ATR and Ddb1-Cul4(Cdt)² ubiquitin ligase-dependent nucleotide synthesis promotes homologous recombination repair in fission yeast.

Moss J, Tinline-Purvis H, Walker CA, Folkes LK, Stratford MR, Hayles J, Hoe KL, Kim DU, Park HO, Kearsey SE, Fleck O, Holmberg C, Nielsen O, Humphrey TC.

Genes Dev. 2010 Dec 1;24(23):2705-16. doi: 10.1101/gad.1970810.

21.

Reactivity of hydrogen sulfide with peroxynitrite and other oxidants of biological interest.

Carballal S, Trujillo M, Cuevasanta E, Bartesaghi S, Möller MN, Folkes LK, García-Bereguiaín MA, Gutiérrez-Merino C, Wardman P, Denicola A, Radi R, Alvarez B.

Free Radic Biol Med. 2011 Jan 1;50(1):196-205. doi: 10.1016/j.freeradbiomed.2010.10.705. Epub 2010 Oct 26.

PMID:
21034811
22.

Effects of acute versus chronic hypoxia on DNA damage responses and genomic instability.

Pires IM, Bencokova Z, Milani M, Folkes LK, Li JL, Stratford MR, Harris AL, Hammond EM.

Cancer Res. 2010 Feb 1;70(3):925-35. doi: 10.1158/0008-5472.CAN-09-2715. Epub 2010 Jan 26.

23.

A phase I trial of radioimmunotherapy with 131I-A5B7 anti-CEA antibody in combination with combretastatin-A4-phosphate in advanced gastrointestinal carcinomas.

Meyer T, Gaya AM, Dancey G, Stratford MR, Othman S, Sharma SK, Wellsted D, Taylor NJ, Stirling JJ, Poupard L, Folkes LK, Chan PS, Pedley RB, Chester KA, Owen K, Violet JA, Malaroda A, Green AJ, Buscombe J, Padhani AR, Rustin GJ, Begent RH.

Clin Cancer Res. 2009 Jul 1;15(13):4484-92. doi: 10.1158/1078-0432.CCR-09-0035. Epub 2009 Jun 23.

24.

Kinetics of reaction of nitrogen dioxide with dihydrorhodamine and the reaction of the dihydrorhodamine radical with oxygen: implications for quantifying peroxynitrite formation in cells.

Folkes LK, Patel KB, Wardman P, Wrona M.

Arch Biochem Biophys. 2009 Apr 15;484(2):122-6. doi: 10.1016/j.abb.2008.10.014. Epub 2008 Oct 19.

PMID:
18976629
25.

Thiyl radicals react with nitric oxide to form S-nitrosothiols with rate constants near the diffusion-controlled limit.

Madej E, Folkes LK, Wardman P, Czapski G, Goldstein S.

Free Radic Biol Med. 2008 Jun 15;44(12):2013-8. doi: 10.1016/j.freeradbiomed.2008.02.015. Epub 2008 Mar 12.

PMID:
18381080
26.

Oxidative metabolism of combretastatin A-1 produces quinone intermediates with the potential to bind to nucleophiles and to enhance oxidative stress via free radicals.

Folkes LK, Christlieb M, Madej E, Stratford MR, Wardman P.

Chem Res Toxicol. 2007 Dec;20(12):1885-94. Epub 2007 Oct 18.

PMID:
17941699
27.

Radiosensitization by nitric oxide at low radiation doses.

Wardman P, Rothkamm K, Folkes LK, Woodcock M, Johnston PJ.

Radiat Res. 2007 Apr;167(4):475-84.

PMID:
17388699
28.

Effect of nitric-oxide synthesis on tumour blood volume and vascular activity: a phase I study.

Ng QS, Goh V, Milner J, Stratford MR, Folkes LK, Tozer GM, Saunders MI, Hoskin PJ.

Lancet Oncol. 2007 Feb;8(2):111-8.

PMID:
17267325
29.

Kinetics of the reaction between nitric oxide and glutathione: implications for thiol depletion in cells.

Folkes LK, Wardman P.

Free Radic Biol Med. 2004 Aug 15;37(4):549-56.

PMID:
15256226
30.

Phase I clinical trial of weekly combretastatin A4 phosphate: clinical and pharmacokinetic results.

Rustin GJ, Galbraith SM, Anderson H, Stratford M, Folkes LK, Sena L, Gumbrell L, Price PM.

J Clin Oncol. 2003 Aug 1;21(15):2815-22. Epub 2003 Jun 13.

PMID:
12807934
31.
32.

Horseradish peroxidase-mediated gene therapy: choice of prodrugs in oxic and anoxic tumor conditions.

Greco O, Rossiter S, Kanthou C, Folkes LK, Wardman P, Tozer GM, Dachs GU.

Mol Cancer Ther. 2001 Dec;1(2):151-60.

33.

Halogenated indole-3-acetic acids as oxidatively activated prodrugs with potential for targeted cancer therapy.

Rossiter S, Folkes LK, Wardman P.

Bioorg Med Chem Lett. 2002 Sep 16;12(18):2523-6.

PMID:
12182852
34.

Pharmacology and toxicity of nicotinamide combined with domperidone during fractionated radiotherapy.

Bussink J, Stratford MR, van der Kogel AJ, Folkes LK, Kaanders JH.

Radiother Oncol. 2002 Jun;63(3):285-91.

PMID:
12142092
35.
36.

5-Fluoroindole-3-acetic acid: a prodrug activated by a peroxidase with potential for use in targeted cancer therapy.

Folkes LK, Greco O, Dachs GU, Stratford MR, Wardman P.

Biochem Pharmacol. 2002 Jan 15;63(2):265-72.

PMID:
11841802
37.

Revisiting the interaction of the radical anion metabolite of nitrofurantoin with glutathione.

Miller C, Folkes LK, Mottley C, Wardman P, Mason RP.

Arch Biochem Biophys. 2002 Jan 1;397(1):113-8.

PMID:
11747317
38.

Measurement of plasma 5-hydroxyindoleacetic acid as a possible clinical surrogate marker for the action of antivascular agents.

Kestell P, Zhao L, Jameson MB, Stratford MR, Folkes LK, Baguley BC.

Clin Chim Acta. 2001 Dec;314(1-2):159-66.

PMID:
11718691
39.

Influence of plasma glutathione levels on radiation mucositis.

Wardman P, Folkes LK, Bentzen SM, Stratford MR, Hoskin PJ, Phillips H, Jackson S.

Int J Radiat Oncol Biol Phys. 2001 Oct 1;51(2):460-4.

PMID:
11583019
40.
41.

Development of a novel enzyme/prodrug combination for gene therapy of cancer: horseradish peroxidase/indole-3-acetic acid.

Greco O, Folkes LK, Wardman P, Tozer GM, Dachs GU.

Cancer Gene Ther. 2000 Nov;7(11):1414-20.

42.

Effect of local radiotherapy for bone pain on urinary markers of osteoclast activity.

Hoskin PJ, Stratford MR, Folkes LK, Regan J, Yarnold JR.

Lancet. 2000 Apr 22;355(9213):1428-9.

PMID:
10791529
43.

Peroxidase-catalyzed effects of indole-3-acetic acid and analogues on lipid membranes, DNA, and mammalian cells in vitro.

Folkes LK, Dennis MF, Stratford MR, Candeias LP, Wardman P.

Biochem Pharmacol. 1999 Feb 15;57(4):375-82.

PMID:
9933025
44.

Toward targeted "oxidation therapy" of cancer: peroxidase-catalysed cytotoxicity of indole-3-acetic acids.

Folkes LK, Candeias LP, Wardman P.

Int J Radiat Oncol Biol Phys. 1998 Nov 1;42(4):917-20.

PMID:
9845122
45.
47.

Enhancement of peroxidase-induced lipid peroxidation by indole-3-acetic acid: effect of antioxidants.

Candeias LP, Folkes LK, Wardman P.

Redox Rep. 1996 Apr;2(2):141-7. doi: 10.1080/13510002.1996.11747041.

PMID:
27405953
48.

Rates of reaction of indoleacetic acids with horseradish peroxidase compound I and their dependence on the redox potentials.

Candeias LP, Folkes LK, Porssa M, Parrick J, Wardman P.

Biochemistry. 1996 Jan 9;35(1):102-8.

PMID:
8555162
49.

Enhancement of lipid peroxidation by indole-3-acetic acid and derivatives: substituent effects.

Candeias LP, Folkes LK, Porssa M, Parrick J, Wardman P.

Free Radic Res. 1995 Nov;23(5):403-18.

PMID:
7581824
50.

Kinetics and mechanisms of hypochlorous acid reactions.

Folkes LK, Candeias LP, Wardman P.

Arch Biochem Biophys. 1995 Oct 20;323(1):120-6.

PMID:
7487057

Supplemental Content

Loading ...
Support Center